(Q41750442)

8 October 2017

1 reference

title

Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis (English)

1 reference

8 October 2017

main subject

visceral leishmaniasis

1 reference

2

Brogden RN

1 reference

8 October 2017

Coukell AJ

1

1 reference

8 October 2017

publication date

1 April 1998

1 reference

8 October 2017

1 reference

8 October 2017

volume

55

1 reference

8 October 2017

issue

4

1 reference

8 October 2017

page(s)

585-612

1 reference

Anaphylactic reactions to liposomal amphotericin

8 October 2017

cites work

1 reference

12 December 2020

Treatment of Mediterranean visceral leishmaniasis

1 reference

12 December 2020

Experience with liposomal Amphotericin-B in 60 patients undergoing high-dose therapy and bone marrow or peripheral blood stem cell transplantation

1 reference

12 December 2020

Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice

1 reference

12 December 2020

Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome)

1 reference

12 December 2020

Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS.

1 reference

12 December 2020

Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial

1 reference

12 December 2020

Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia

1 reference

12 December 2020

Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations

1 reference

12 December 2020

Treatment of deep mycoses with liposomal amphotericin B

1 reference

12 December 2020

Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients

1 reference

12 December 2020

Adverse drug reactions to systemic antifungals. Prevention and management

1 reference

12 December 2020

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

1 reference

12 December 2020

Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.

1 reference

12 December 2020

Liposomal amphotericin B therapy of murine histoplasmosis

1 reference

12 December 2020

Antifungal chemotherapy in patients with acquired immunodeficiency syndrome. British Society for Antimicrobial Chemotherapy Working Party

1 reference

12 December 2020

Liposomal amphotericin (AmBisome) is safe in bone marrow transplantation for primary immunodeficiency

1 reference

12 December 2020

Multifocal osteoarthritis due to Candida albicans in a neonate: serum level monitoring of liposomal amphotericin B and literature review

1 reference

12 December 2020

Costs of antifungal prophylaxis after bone marrow transplantation. A model comparing oral fluconazole, liposomal amphotericin and oral polyenes as prophylaxis against oropharyngeal infections

1 reference

12 December 2020

Successful treatment of Curvularia sp infection in a patient with primarily resistant acute promyelocytic leukemia.

1 reference

12 December 2020

Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis

1 reference

12 December 2020

Liposomal amphotericin B and recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) in the treatment of paediatric AIDS-related cryptococcosis

1 reference

12 December 2020

Estimation of population at risk of infection and number of cases of Leishmaniasis

1 reference

12 December 2020

Which is the most appropriate dosage of liposomal Amphotericin-B (AmBisome) for the treatment of fungal infections in infants of very low birth weight?

1 reference

12 December 2020

Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis.

1 reference

12 December 2020

Lipid-based amphotericin B in the treatment of cryptococcosis

1 reference

12 December 2020

Clinical use of liposomal and lipid-complexed amphotericin B.

1 reference

12 December 2020

Anaphylaxis due to liposomal amphotericin (AmBisome)

1 reference

12 December 2020

Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients

1 reference

12 December 2020

Lipid formulations of amphotericin B. Less toxicity but at what economic cost?

1 reference

12 December 2020

Efficacy of liposomal amphotericin B (AmBisome) in the eradication of Fusarium infection in a leukaemic patient

1 reference

12 December 2020

Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome)

1 reference

12 December 2020

Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data

1 reference

12 December 2020

Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years

1 reference

12 December 2020

Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host

1 reference

12 December 2020

Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients

1 reference

12 December 2020

Liposomal amphotericin B and continuous venous-venous haemofiltration

1 reference

12 December 2020

Antifungal drug susceptibility testing. Working Party of the British Society for Antimicrobial chemotherapy

1 reference

12 December 2020

Liposomal aerosols in the management of pulmonary infections

1 reference

12 December 2020

Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients

1 reference

12 December 2020

Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study

1 reference

12 December 2020

Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits

1 reference

12 December 2020

Liposomal amphotericin-B (AmBisome) for treatment of disseminated fungal infections in two infants of very low birth weight

1 reference

12 December 2020

Liposomal Amphotericin B Therapy in Disseminated Histoplasmosis

1 reference

12 December 2020

In-vitro effects of liposome-encapsulated amphotericin B (AmBisome) and amphotericin B-deoxycholate (Fungizone) on the phagocytic and candidacidal function of human polymorphonuclear leucocytes

1 reference

12 December 2020

Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials

1 reference

12 December 2020

Allergic reactions and other rare side-effects of liposomal amphotericin.

1 reference

12 December 2020

Elimination of liposomal amphotericin by hemodiafiltration

1 reference

12 December 2020

High cure rate of invasive fungal infections in immunocompromised children using ambisome

1 reference

12 December 2020

Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis

1 reference

12 December 2020

Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony-stimulating factor, and surgery: report of five cases

1 reference

12 December 2020

Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions

1 reference

12 December 2020

Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice

1 reference

12 December 2020

Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B.

1 reference

12 December 2020

Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses

1 reference

12 December 2020

Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice

1 reference

12 December 2020

Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)

1 reference

12 December 2020

Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents

1 reference

12 December 2020

Problems and controversies in the management of hematogenous candidiasis

1 reference

12 December 2020

Successful combined surgical and medical treatment of fusarium infection after bone marrow transplantation

1 reference

12 December 2020

Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice

1 reference

12 December 2020

Treatment of visceral leishmaniasis in children with liposomal amphotericin B

1 reference

12 December 2020

Liposomal amphotericin B as early empiric antimycotic therapy of pneumonia in granulocytopenic patients

1 reference

12 December 2020

Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial

1 reference

12 December 2020

Immunological effects of amphotericin B and liposomal amphotericin B on splenocytes from immune-normal and immune-compromised mice

1 reference

12 December 2020

Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum

1 reference

12 December 2020

Amphotericin B: an update.

1 reference

12 December 2020

Extrapulmonary cryptococcosis in children with acquired immunodeficiency syndrome

1 reference

12 December 2020

Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics

1 reference

12 December 2020

Ventricular arrhythmias with conventional and liposomal amphotericin

1 reference

12 December 2020

Cure of Rhizopus sinusitis in a liver transplant recipient with liposomal amphotericin B

1 reference

12 December 2020

Targeting fungi: a challenge

1 reference

12 December 2020

Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection.

1 reference

12 December 2020

Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis.

1 reference

12 December 2020

Pretreatment regimens for adverse events related to infusion of amphotericin B.

1 reference

12 December 2020

Severe candidal infections in neutropenic patients

1 reference

12 December 2020

Clinical use of amphotericin B and derivatives: lore, mystique, and fact

1 reference

12 December 2020

Standardization of antifungal susceptibility testing

1 reference

12 December 2020

Anaphylactic reaction to liposomal amphotericin B in children

1 reference

12 December 2020

Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum

1 reference

12 December 2020

Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia

1 reference

12 December 2020

Recent advances in the management of cryptococcal meningitis in patients with AIDS.

1 reference

12 December 2020

Efficacy of AmBisome in murine coccidioidomycosis.

1 reference

12 December 2020

Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long-term results of a randomized, placebo-controlled trial.

1 reference

12 December 2020

The changing epidemiology of fungal infections: are the lipid-forms of amphotericin B an advance?

1 reference

12 December 2020

Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin.

1 reference

12 December 2020

10.2165/00003495-199855040-00008

Identifiers

DOI

1 reference

Dimensions Publication ID

8 October 2017

1037108316

0 references

1 reference